197 related articles for article (PubMed ID: 33051436)
1. FBI-1 enhanced the resistance of triple-negative breast cancer cells to chemotherapeutic agents via the miR-30c/PXR axis.
Yang H; Ren L; Wang Y; Bi X; Li X; Wen M; Zhang Q; Yang Y; Jia Y; Li Y; Zang A; Wei Y; Dai G
Cell Death Dis; 2020 Oct; 11(10):851. PubMed ID: 33051436
[TBL] [Abstract][Full Text] [Related]
2. SPAG5 upregulation contributes to enhanced c-MYC transcriptional activity via interaction with c-MYC binding protein in triple-negative breast cancer.
Li M; Li A; Zhou S; Lv H; Yang W
J Hematol Oncol; 2019 Feb; 12(1):14. PubMed ID: 30736840
[TBL] [Abstract][Full Text] [Related]
3. LncRNA DLX6-AS1 Contributes to Epithelial-Mesenchymal Transition and Cisplatin Resistance in Triple-negative Breast Cancer via Modulating Mir-199b-5p/Paxillin Axis.
Du C; Wang Y; Zhang Y; Zhang J; Zhang L; Li J
Cell Transplant; 2020; 29():963689720929983. PubMed ID: 32686982
[TBL] [Abstract][Full Text] [Related]
4. microRNA-761 induces aggressive phenotypes in triple-negative breast cancer cells by repressing TRIM29 expression.
Guo GC; Wang JX; Han ML; Zhang LP; Li L
Cell Oncol (Dordr); 2017 Apr; 40(2):157-166. PubMed ID: 28054302
[TBL] [Abstract][Full Text] [Related]
5. WBP2 Downregulation Inhibits Proliferation by Blocking YAP Transcription and the EGFR/PI3K/Akt Signaling Pathway in Triple Negative Breast Cancer.
Song H; Wu T; Xie D; Li D; Hua K; Hu J; Fang L
Cell Physiol Biochem; 2018; 48(5):1968-1982. PubMed ID: 30092563
[TBL] [Abstract][Full Text] [Related]
6. Rhamnetin decelerates the elimination and enhances the antitumor effect of the molecular-targeting agent sorafenib in hepatocellular carcinoma cells via the miR-148a/PXR axis.
Li B; Feng F; Jia H; Jiang Q; Cao S; Wei L; Zhang Y; Lu J
Food Funct; 2021 Mar; 12(6):2404-2417. PubMed ID: 33570057
[TBL] [Abstract][Full Text] [Related]
7. Suppressive role exerted by microRNA-29b-1-5p in triple negative breast cancer through SPIN1 regulation.
Drago-Ferrante R; Pentimalli F; Carlisi D; De Blasio A; Saliba C; Baldacchino S; Degaetano J; Debono J; Caruana-Dingli G; Grech G; Scerri C; Tesoriere G; Giordano A; Vento R; Di Fiore R
Oncotarget; 2017 Apr; 8(17):28939-28958. PubMed ID: 28423652
[TBL] [Abstract][Full Text] [Related]
8. MicroRNA 603 acts as a tumor suppressor and inhibits triple-negative breast cancer tumorigenesis by targeting elongation factor 2 kinase.
Bayraktar R; Pichler M; Kanlikilicer P; Ivan C; Bayraktar E; Kahraman N; Aslan B; Oguztuzun S; Ulasli M; Arslan A; Calin G; Lopez-Berestein G; Ozpolat B
Oncotarget; 2017 Feb; 8(7):11641-11658. PubMed ID: 28036267
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA-137 represses FBI-1 to inhibit proliferation and in vitro invasion and migration of hepatocellular carcinoma cells.
Zhu M; Li M; Wang T; Linghu E; Wu B
Tumour Biol; 2016 Oct; 37(10):13995-14008. PubMed ID: 27492460
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA-101 inhibits cell progression and increases paclitaxel sensitivity by suppressing MCL-1 expression in human triple-negative breast cancer.
Liu X; Tang H; Chen J; Song C; Yang L; Liu P; Wang N; Xie X; Lin X; Xie X
Oncotarget; 2015 Aug; 6(24):20070-83. PubMed ID: 26036638
[TBL] [Abstract][Full Text] [Related]
11. Arrestin Domain Containing 3 Reverses Epithelial to Mesenchymal Transition and Chemo-Resistance of TNBC Cells by Up-Regulating Expression of miR-200b.
Soung YH; Chung H; Yan C; Ju J; Chung J
Cells; 2019 Jul; 8(7):. PubMed ID: 31295851
[TBL] [Abstract][Full Text] [Related]
12. MiR-193 promotes cell proliferation and invasion by ING5/PI3K/AKT pathway of triple-negative breast cancer.
Xu JH; Zhao JX; Jiang MY; Yang LP; Sun ML; Wang HW
Eur Rev Med Pharmacol Sci; 2020 Mar; 24(6):3122-3129. PubMed ID: 32271430
[TBL] [Abstract][Full Text] [Related]
13. lncRNA GAS5-promoted apoptosis in triple-negative breast cancer by targeting miR-378a-5p/SUFU signaling.
Zheng S; Li M; Miao K; Xu H
J Cell Biochem; 2020 Mar; 121(3):2225-2235. PubMed ID: 31692053
[TBL] [Abstract][Full Text] [Related]
14. Knockdown of PC4 increases chemosensitivity of Oxaliplatin in triple negative breast cancer by suppressing mTOR pathway.
Wang Q; Ma L; Chen L; Chen H; Luo M; Yang W; Liao F; Gong Q; Wang Y; Yang Z; Wu J; Zhang C; Zheng J; Han S; Leng Y; Luo P; Shi C
Biochem Biophys Res Commun; 2021 Mar; 544():65-72. PubMed ID: 33524870
[TBL] [Abstract][Full Text] [Related]
15. Curcumol enhances the sensitivity of doxorubicin in triple-negative breast cancer via regulating the miR-181b-2-3p-ABCC3 axis.
Zeng C; Fan D; Xu Y; Li X; Yuan J; Yang Q; Zhou X; Lu J; Zhang C; Han J; Gu J; Gao Y; Sun L; Wang S
Biochem Pharmacol; 2020 Apr; 174():113795. PubMed ID: 31926937
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of retinoic acid receptor α phosphorylation represses the progression of triple-negative breast cancer via transactivating miR-3074-5p to target DHRS3.
Lou S; Gao H; Hong H; Zhu Z; Zhao H
J Exp Clin Cancer Res; 2021 Apr; 40(1):141. PubMed ID: 33902658
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of miR-361-5p in triple-negative breast cancer (TNBC) inhibits migration and invasion by targeting RQCD1 and inhibiting the EGFR/PI3K/Akt pathway.
Han J; Yu J; Dai Y; Li J; Guo M; Song J; Zhou X
Bosn J Basic Med Sci; 2019 Feb; 19(1):52-59. PubMed ID: 29924958
[TBL] [Abstract][Full Text] [Related]
18. [Effects of FBI-1 silencing on proliferation and apoptosis of triple-negative breast cancer cell line MDA-MB-231].
Chen MJ; Wang L; Yang WP; Qin QH; Tan QX; Lian B; Wei CY
Sheng Li Xue Bao; 2018 Oct; 70(5):497-503. PubMed ID: 30377688
[TBL] [Abstract][Full Text] [Related]
19. MiR-770 suppresses the chemo-resistance and metastasis of triple negative breast cancer via direct targeting of STMN1.
Li Y; Liang Y; Sang Y; Song X; Zhang H; Liu Y; Jiang L; Yang Q
Cell Death Dis; 2018 Jan; 9(1):14. PubMed ID: 29323124
[TBL] [Abstract][Full Text] [Related]
20. Prexasertib treatment induces homologous recombination deficiency and synergizes with olaparib in triple-negative breast cancer cells.
Mani C; Jonnalagadda S; Lingareddy J; Awasthi S; Gmeiner WH; Palle K
Breast Cancer Res; 2019 Sep; 21(1):104. PubMed ID: 31492187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
